pandem
caus
million
infect
januarymarch
urgent
need
robust
antibodi
detect
approach
support
diagnost
vaccin
develop
safe
individu
releas
quarantin
popul
lockdown
exit
strategi
earli
promis
later
flow
immunoassay
lfia
devic
question
follow
concern
sensit
specif
use
panel
plasma
sampl
design
posit
rtpcrposit
individu
neg
sampl
bank
uk
prior
test
plasma
igm
igg
antibodi
elisa
use
nine
differ
commerci
avail
lfia
devic
result
elisa
detect
igm
igg
individu
rtpcrconfirm
diagnosi
infect
sensit
ci
vs
prepandem
control
specif
ci
igg
level
detect
rtpcrposit
individu
test
day
symptom
onset
sensit
ci
igg
titr
rose
week
post
symptom
onset
began
fall
week
remain
detect
threshold
point
estim
sensit
lfia
devic
rang
versu
rtpcr
versu
elisa
specif
respect
within
limit
studi
size
perform
lfia
devic
similar
perform
current
lfia
devic
inadequ
individu
patient
applic
elisa
calibr
specif
detect
quantifi
igm
igg
highli
sensit
igg
day
follow
symptom
onset
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
primari
target
specif
neutralis
antibodi
current
serolog
assay
therefor
typic
seek
identifi
antibodi
figur
rapid
later
flow
immunoassay
lfia
devic
provid
quick
pointofcar
approach
antibodi
test
sensit
specif
antibodi
assay
could
directli
contribut
earli
identif
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
isol
case
address
unknown
regard
extent
infect
inform
mathemat
model
support
individu
populationlevel
releas
lockdown
howev
either
laboratori
assay
lfia
devic
wide
deploy
perform
characterist
need
evalu
figur
e
therefor
compar
novel
laboratorybas
elisa
assay
nine
commerciallyavail
lfia
devic
use
sampl
patient
rtpcrconfirm
infect
neg
prepandem
sampl
method
plasma
sampl
design
seroneg
collect
adult
year
uk
decemb
tabl
three
ethic
approv
sourc
healthi
blood
donor
organ
donor
icu
follow
cerebr
injuri
healthi
volunt
vaccin
studi
bert
forti
plasma
sampl
collect
adult
posit
rtpcr
upper
respiratori
tract
nosethroat
swab
test
accredit
laboratori
tabl
acut
day
symptom
onset
convalesc
sampl
day
includ
optimis
detect
specif
igm
igg
respect
figur
acut
sampl
collect
patient
median
rang
day
symptom
onset
recov
healthcar
worker
median
rang
day
first
symptom
convalesc
sampl
collect
adult
median
rang
day
symptom
onset
andor
date
posit
throat
swab
sampl
detail
supplementari
materi
case
classifi
follow
criteria
critic
respiratori
failur
septic
shock
andor
multipl
organ
dysfunctionfailur
sever
dyspnoea
respiratori
frequenc
blood
oxygen
satur
ratio
andor
lung
infiltr
lung
field
within
hour
otherwis
mild
among
acut
case
critic
sever
mild
one
convalesc
individu
mild
diseas
asymptomat
screen
enhanc
contact
trace
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
first
case
infect
novel
coronaviru
subsequ
design
emerg
wuhan
china
decemb
st
despit
intens
contain
effort
rapid
intern
spread
three
month
later
caus
million
confirm
infect
report
death
contain
effort
reli
heavili
popul
quarantin
lockdown
measur
restrict
movement
reduc
individu
contact
develop
public
health
strategi
exit
lockdown
diagnost
test
urgent
need
scaledup
includ
mass
screen
screen
specif
highrisk
group
contact
confirm
case
healthcar
worker
famili
parallel
collect
robust
data
recent
past
exposur
individu
popul
level
laboratori
diagnosi
infect
mostli
base
realtim
rtpcr
typic
target
viral
rnadepend
rna
polymeras
rdrp
nucleocapsid
n
gene
use
swab
collect
upper
respiratori
tract
requir
specialist
equip
skill
laboratori
staff
pcr
reagent
creat
diagnost
delay
rtpcr
upper
respiratori
tract
swab
may
also
fals
neg
due
qualiti
time
viral
load
upper
respiratori
tract
secret
peak
first
week
symptom
may
declin
limit
detect
present
later
individu
recov
rtpcr
provid
inform
prior
exposur
immun
contrast
assay
reliabl
detect
antibodi
respons
specif
could
contribut
diagnosi
acut
infect
via
rise
igm
igg
level
identifi
infect
without
symptom
recov
via
persist
igg
receptormedi
viral
entri
host
cell
occur
interact
uniqu
highlyconserv
spike
glycoprotein
cell
receptor
protein
use
novel
elisa
recombin
trimer
spike
protein
construct
tag
purifi
immunopl
coat
strepmabclass
use
captur
tag
solubl
trimer
trimer
protein
incub
test
plasma
antibodi
bind
protein
detect
alpconjug
antihuman
igg
antihuman
igm
detail
supplementari
materi
test
lfia
devic
design
detect
igm
igg
total
antibodi
produc
nine
manufactur
shortlist
test
prioriti
uk
govern
depart
health
social
care
dhsc
base
apprais
devic
proven
avail
perform
data
individu
manufactur
approv
releas
devicelevel
data
devic
name
anonymis
test
perform
strict
accord
manufactur
instruct
devic
typic
involv
ad
plasma
sampl
well
manufactur
buffer
adjac
well
follow
incub
room
temperatur
minut
result
base
appear
colour
band
design
posit
control
test
band
present
neg
control
band
invalid
band
absent
control
band
band
wrong
place
figur
record
result
realtim
passwordprotect
electron
databas
use
pseudonymis
sampl
identifi
captur
readout
devic
positivenegativeinvalid
oper
devic
devic
batch
number
timestamp
photograph
devic
test
sampl
use
elisa
quantifi
igm
igg
antibodi
plasma
design
neg
posit
posit
sampl
includ
unstratifi
random
sampl
neg
plasma
healthi
blood
donor
organ
donor
test
nine
differ
lfia
devic
use
individu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
plasma
sampl
sampl
design
posit
neg
respect
tabl
total
number
vari
accord
number
devic
suppli
dhsc
sampl
otherwis
select
random
analys
conduct
use
r
version
stata
version
addit
plot
gener
use
graphpad
prism
version
binomi
confid
interv
ci
calcul
proport
associ
elisa
result
time
sinc
symptom
onset
sever
need
hospit
admiss
age
estim
use
multivari
linear
regress
without
variabl
select
nonlinear
relationship
continu
factor
includ
via
natur
cubic
spline
differ
lfia
devic
estim
use
mix
effect
logist
regress
model
allow
devic
test
overlap
sampl
set
differ
devic
compar
benjaminihochberg
correct
pvalu
threshold
detail
supplementari
materi
forti
posit
rtpcrconfirm
infect
design
neg
prepandem
plasma
sampl
test
elisa
characteris
antibodi
profil
neg
sampl
median
optic
densiti
od
igm
arbitrari
unit
rang
igg
rang
median
igm
read
posit
sampl
rang
kruskalw
p
vs
neg
igg
median
rang
p
safe
individu
releas
lockdown
major
applic
serolog
test
chose
od
threshold
maintain
specif
ci
maximis
sensit
use
threshold
igm
igg
standard
deviat
neg
mean
respect
figur
b
igg
assay
sensit
ci
vs
rtpcr
diagnosi
six
falseneg
sampl
taken
within
day
symptom
onset
figur
igg
level
detect
rtpcrposit
individu
test
day
symptom
onset
sensit
ci
igm
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
assay
sensit
lower
ci
igg
falseneg
igmneg
patient
igmposit
iggneg
consid
relationship
igm
igg
titr
time
sinc
symptom
onset
figur
univari
regress
model
show
igg
antibodi
titr
rise
first
week
symptom
onset
lower
bound
pointwis
ci
mean
expect
titr
cross
od
threshold
day
figur
howev
given
sampl
variat
test
perform
like
optim
sever
day
later
igg
titr
fell
second
month
symptom
onset
remain
od
threshold
tempor
associ
observ
igm
titr
time
sinc
symptom
onset
figur
evid
sever
need
hospit
admiss
patient
age
associ
igg
igm
titr
multivari
model
p
tabl
first
consid
perform
nine
differ
lfia
devic
use
rtpcrconfirm
case
refer
standard
tabl
figur
consid
lfia
posit
result
igm
igg
posit
lfia
devic
achiev
sensit
rang
ci
specif
ci
evid
differ
devic
sensit
cf
benjaminihochberg
threshold
specif
devic
least
one
falseposit
test
restrict
sampl
collect
day
post
symptomonset
elisa
iggposit
lfia
sensit
rang
ci
tabl
also
consid
perform
rel
elisa
tabl
figur
lfia
devic
target
antibodi
consid
patient
posit
altern
standard
igg
od
read
exceed
threshold
sinc
sampl
igmposit
iggneg
sensit
antibodi
detect
lfia
rang
ci
specif
ci
howev
devic
highest
sensit
one
lowest
specif
figur
evid
differ
sensit
cf
threshold
specif
devic
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
design
neg
sampl
test
elisa
nine
differ
lfia
devic
nine
separ
sampl
gener
least
one
falseposit
seven
differ
lfia
devic
figur
four
sampl
gener
falseposit
result
one
lfia
devic
despit
absenc
quantifi
igm
igg
elisa
potenti
suggest
specif
attribut
sampl
caus
crossreact
certain
lfia
platform
elisa
present
perform
characterist
novel
elisa
nine
lfia
devic
detect
igm
igg
use
panel
refer
plasma
set
threshold
detect
use
neg
prepandem
control
rtpcrconfirm
posit
patient
igg
detect
elisa
includ
patient
test
day
symptom
onset
panel
lfia
devic
sensit
referencestandard
rtpcr
elisa
specif
respect
estim
come
rel
wide
confid
interv
due
constraint
number
devic
made
avail
test
nevertheless
studi
provid
benchmark
assess
perform
platform
detect
igmigg
aim
guid
decis
deploy
antibodi
test
inform
design
assess
secondgener
assay
lfia
devic
cheap
manufactur
store
distribut
could
use
pointofcar
test
healthcar
practition
individu
home
offer
appeal
approach
diagnost
evalu
individu
populationlevel
exposur
posit
antibodi
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
test
current
regard
probabl
surrog
immun
reinfect
secur
confirm
antibodi
statu
would
therefor
reduc
anxieti
provid
confid
allow
individu
relax
social
distanc
measur
guid
policymak
stage
releas
popul
lockdown
potenti
tandem
digit
approach
contact
trace
diagnost
tool
serolog
may
role
combin
rtpcr
test
improv
sensit
particularli
case
present
sometim
symptom
onset
reproduc
method
detect
quantifi
vaccinemedi
antibodi
also
crucial
vaccin
enter
clinic
trial
evalu
magnitud
durabl
immunogen
appropri
threshold
sensit
specif
antibodi
test
depend
purpos
must
consid
plan
deploy
diagnosi
symptomat
patient
high
sensit
requir
gener
specif
less
critic
falseposit
could
toler
provid
potenti
diagnos
consid
accept
overdiagnosi
caus
unnecessari
quarantin
hospit
admiss
howev
antibodi
test
deploy
individuallevel
approach
inform
releas
quarantin
high
specif
essenti
falseposit
result
return
nonimmun
individu
risk
exposur
reason
uk
medicin
healthcar
product
regulatori
agenc
set
minimum
specif
threshold
lfia
apprais
test
perform
also
consid
influenc
popul
preval
acknowledg
chang
time
geographi
within
differ
popul
group
eg
healthcar
worker
teacher
potenti
risk
test
provid
fals
reassur
releas
lockdown
nonimmun
individu
consid
proport
posit
test
wrong
well
number
incorrect
posit
test
per
peopl
test
base
work
best
case
scenario
lfia
test
sensit
specif
proport
posit
test
wrong
popul
seropreval
test
seropreval
seropreval
figur
howev
data
need
investig
antibodyposit
correl
protect
immun
inde
preexist
igg
could
enhanc
diseas
situat
anim
data
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
demonstr
sarscov
antispik
igg
contribut
proinflammatori
respons
associ
lung
injuri
macaqu
data
kinet
antibodi
respons
infect
build
upon
studi
hospitalis
patient
china
report
median
day
seroconvers
total
antibodi
igm
igg
seroconvers
day
respect
anoth
similar
studi
report
igg
posit
day
elisa
data
show
igg
titr
rose
first
week
infect
igm
test
identifi
addit
case
method
enhanc
sensit
especi
shortli
symptom
onset
could
consid
differ
sampl
type
eg
saliva
differ
antibodi
class
eg
iga
tcell
assay
antigen
detect
contrast
other
find
evid
associ
diseas
sever
antibodi
titr
observ
sever
lfia
fals
posit
may
potenti
result
crossreact
nonspecif
antibodi
eg
reflect
past
exposur
season
coronaviru
infect
main
studi
limit
number
test
small
provid
tight
confid
interv
around
perform
estim
specif
lfia
devic
expand
test
across
divers
popul
would
increas
certainti
given
broadli
compar
perform
differ
assay
cost
manpow
test
larg
number
may
justifi
demonstr
high
specif
particularli
challeng
exampl
true
underli
valu
neg
control
would
requir
estim
specif
assay
approxim
power
full
assess
also
includ
rang
geograph
locat
ethnic
group
children
immunolog
diseas
includ
autoimmun
condit
immunosuppress
summari
antibodi
test
crucial
inform
releas
lockdown
studi
offer
insight
perform
novel
elisa
panel
lfia
devic
made
wide
avail
date
limit
systemat
valid
find
suggest
current
lfia
devic
may
provid
inform
populationlevel
survey
perform
inadequ
individu
patient
applic
biobank
sampl
assembl
studi
continu
expand
provid
valuabl
resourc
develop
next
gener
elisa
later
flow
assay
elisa
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
describ
current
optimis
adapt
run
highthroughput
platform
provid
promis
develop
reliabl
approach
antibodi
detect
support
decis
make
clinician
public
health
commun
policymak
industri
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
result
gener
sampl
relev
metadata
provid
tabl
work
use
data
sampl
provid
patient
collect
nh
part
care
support
extrem
grate
frontlin
nh
clinic
research
staff
volunt
medic
student
collect
data
challeng
circumst
generos
particip
famili
individu
contribut
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
integrum
scientif
llc
greensboro
nc
usa
outsid
submit
work
asw
report
grant
nihr
conduct
studi
author
conflict
interest
declar
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
posit
test
igg
igm
total
antibodi
shown
posit
pleas
see
figur
detail
breakdown
grey
block
indic
miss
data
result
insuffici
devic
test
sampl
one
assay
one
devic
invalid
result
sampl
panel
rank
left
right
quantit
igg
indic
panel
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
